Methods of Determining Irritable Bowel Syndrome and Efficiency of Probiotics in Treatment: A Review

被引:6
作者
Ahlawat, Geetika M. [1 ]
Singh, Prabhat K. [2 ,3 ,4 ]
机构
[1] Chandigarh Univ, Dept Biotechnol, Mohali, Punjab, India
[2] Bhabha Atom Res Ctr, Radiat & Photochem Div, Mumbai, Maharashtra, India
[3] Homi Bhabha Natl Inst, Training Sch Complex, Mumbai, Maharashtra, India
[4] Bhabha Atom Res Ctr, Radiat & Photochem Div, Mumbai 400085, Maharashtra, India
来源
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL | 2023年 / 99卷
关键词
Blastocystis; Gut-brain axis; Gut microbiota; Irritable bowel syndrome; Probiotics; Saccharomyces boulardii; RANDOMIZED CLINICAL-TRIAL; LOW-FODMAP DIET; DOUBLE-BLIND; SACCHAROMYCES-BOULARDII; FECAL MICROBIOTA; PLACEBO; SYMPTOMS; EFFICACY; MANAGEMENT; CONSENSUS;
D O I
10.1016/j.curtheres.2023.100721
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: Irritable bowel syndrome (IBS) is a prevalent lifestyle-associated ailment linked to the gut microbiota that significantly influences patients' quality of life. A notable correlation exists between Blastocystis infections and susceptibility to IBS, with infected individuals exhibiting an increased likelihood of developing the condition. Despite promising results from using probiotics to modulate the gut microbiota and manage IBS, the precise mechanisms and potential risks remain unclear.Objective: This review aims to explore the therapeutic potential of probiotics, particularly Saccharomyces boulardii, in the management of IBS, highlighting the role of the gut microbiota and the gut-brain axis in IBS pathophysiology.Methods: A comprehensive literature survey was conducted to examine the association between gut microbiota and IBS, the role of probiotics in managing IBS, the mechanisms of their action, and the potential risks associated with their long-term use. Additionally, this study addresses the influence of Blastocystis infections on IBS susceptibility and evaluates various ongoing clinical trials investigating probiotic use for IBS.Results: S boulardii, a yeast species with probiotic properties, has demonstrated effectiveness in both the treatment and prophylaxis of IBS. Its administration is associated with a decrease in the proinflammatory cytokine interleukin 8 and an increase in the anti-inflammatory cytokine interleukin 10. Probiotics appear to function by inhibiting the growth of pathogenic microorganisms and regulating neurotransmitter activity, influencing the gut-brain axis. However, selecting appropriate probiotic strains and dosing regimens is crucial because of potential adverse effects, such as infections and allergic reactions.Conclusions: Probiotics, specifically S boulardii, offer a promising avenue for IBS management by modulating gut microbiota. However, further research is necessary to delineate the precise mechanisms of action, optimal strains, dosing regimens for IBS treatment, and potential risks associated with long-term use. A comprehensive approach incorporating probiotics, a low-FODMAP diet, and cognitive-behavioral therapy may provide effective management of IBS symptoms.(c) 2023 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )
引用
收藏
页数:8
相关论文
共 48 条
[1]  
ABDELLAH SA, 2022, DIGEST DIS 0825, pNIL1, DOI DOI 10.1159/000526712
[2]   Associations of neurotransmitters and the gut microbiome with emotional distress in mixed type of irritable bowel syndrome [J].
Barandouzi, Zahra A. ;
Lee, Joochul ;
Rosas, Maria Del Carmen ;
Chen, Jie ;
Henderson, Wendy A. ;
Starkweather, Angela R. ;
Cong, Xiaomei S. .
SCIENTIFIC REPORTS, 2022, 12 (01)
[3]   Selective Serotonin Reuptake Inhibitors for the Treatment of Irritable Bowel Syndrome [J].
Bundeff, Andrew W. ;
Woodis, C. Brock .
ANNALS OF PHARMACOTHERAPY, 2014, 48 (06) :777-784
[4]   AGA Technical Review on the Evaluation of Functional Diarrhea and Diarrhea-Predominant Irritable Bowel Syndrome in Adults (IBS-D) [J].
Carrasco-Labra, Alonso ;
Lytvyn, Lyubov ;
Falck-Ytter, Yngve ;
Surawicz, Christina M. ;
Chey, William D. .
GASTROENTEROLOGY, 2019, 157 (03) :859-880
[5]   Evaluating the Efficacy of Probiotics in IBS Treatment Using a Systematic Review of Clinical Trials and Multi-Criteria Decision Analysis [J].
Ceccherini, Cecilia ;
Daniotti, Sara ;
Bearzi, Claudia ;
Re, Ilaria .
NUTRIENTS, 2022, 14 (13)
[6]   Effects of baseline abdominal pain and bloating on response to lubiprostone in patients with irritable bowel syndrome with constipation [J].
Chang, L. ;
Chey, W. D. ;
Drossman, D. ;
Losch-Beridon, T. ;
Wang, M. ;
Lichtlen, P. ;
Mareya, S. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2016, 44 (10) :1114-1122
[7]  
Chey WD, 2011, Gastroenterology, V140, pS, DOI [10.1016/S0016-5085(11)60550-7, DOI 10.1016/S0016-5085(11)60550-7]
[8]   A Randomized, Double-blind, Placebo-controlled Multicenter Trial of Saccharomyces boulardii in Irritable Bowel Syndrome Effect on Quality of Life [J].
Choi, Chang Hwan ;
Jo, Sun Young ;
Park, Hyo Jin ;
Chang, Sae Kyung ;
Byeon, Jeong-Sik ;
Myung, Seung-Jae .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 2011, 45 (08) :679-683
[9]   The Microbiome and Irritable Bowel Syndrome - A Review on the Pathophysiology, Current Research and Future Therapy [J].
Chong, Pei Pei ;
Chin, Voon Kin ;
Looi, Chung Yeng ;
Wong, Won Fen ;
Madhavan, Priya ;
Yong, Voon Chen .
FRONTIERS IN MICROBIOLOGY, 2019, 10
[10]   Yeast as probiotics - Saccharomyces boulardii [J].
Czerucka, D. ;
Piche, T. ;
Rampal, P. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2007, 26 (06) :767-778